Current issue

Issue image

Volume 39, Issue 1, 2025

Online ISSN: 3042-3511

ISSN: 3042-3503

Volume 39 , Issue 1, (2025)

Published: 31.03.2025.

Open Access

Welcome to Issue 39, No. 1 – the first of our two annual publications for this year. Inside, you'll find a curated selection of articles. Start your year with the essential knowledge and perspectives offered in this timely edition

All issues

More Filters

Contents

01.01.2021.

Case Reports

COVID19 polyneuropathy therapy with high doses of alpha-lipoic acid- Case report

The aim of our work is to acquaint other fellow physicians with our experience in prescribing high doses of ALA to which there was only a therapeutic response in terms of significant reduction of neuropathic ailments in our patients. We continued the therapy for six months after the introduction, because the difficulties are still maintained, now in a very mild form. COVID-19 disease caused by the SARS-CoV-2 virus was first described in December 2019 in Wuhan, China, but has since spread rapidly globally. Although the number of cases and deaths has attracted a lot of media attention, less attention is paid to the long-term tribute taken by those who survived the disease Since the discovery, there have been more and more reports linking SARSCoV-2 infection to various nervous system disorders. These disorders can be broken down into processes that affect the brain and spinal cord that make up the central nervous system or CNS, as well as those that affect the peripheral nervous system or PNS. Every day we learn more about the spectrum of neuromuscular disorders that develop after COVID-19 disease. We present two patients with polyneuropathy after proven SARSCoV-2 virus infection, aged 37 and 45, without previous chronic diseases that may be associated with peripheral nerve damage. The dominant symptoms in both patients are weakness and unpleasant sensations in the hands and feet, fatigue and general weakness. Therapy with high doses of alpha-lipoic acid has led to a significant reduction in discomfort and improved quality of life of patients.

Željko Kaganović, Sladjana Pavic, Zorica Tanasković

01.05.2021.

Case Reports

Cerebralni vasculitis caused by Toxocara canis: Case report

We present a case of cerebral vasculitis and suspicious retinal vasculitis of a thirty-five- year old, HIV-negative woman. Toxocara canis is a ubiquitous parasite found worldwide. She can only complete lifecycle in dogs, and humans are accidental hosts. Among the neurological and neuropsychological disturbances produced by Toxocara infection, in humans, the most representative are meningitis, encephalitis, myelitis and cerebral vasculitis. Predominant symptoms were trembling and tingling in the left side of the body, tremor of the hands and weakness of the extremities, more to the left, fever and visual disturbance. MR imaging of the brain showed obliterative endarteritis to the left. Visual acuity was impaired, the optic nerve was swollen and macula was thickened. Antibodies to Toxocara canis were detected by ELISA test. Antiparasitic therapy with corticosteroids has led to the reduction of symptoms and clinical findings.

Sladjana Pavic, Zeljko Kaganovic

Partners